Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.


Good Riddance to a Bad Drug
Dr. Eric Topol, The New York Times, 10-2-04

This op-ed, by one of the researchers who published a paper in 2001 arguing that Vioxx use gave rise to increased risk of heart attack, nicely puts forth the arguments in favor of stronger FDA standards for safety research and restrictions on direct-to-consumer advertising. Read it in tandem with the Journal piece.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000